Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Danegaptide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE known ✓ | P12821 | 3/20 | 0.43 |
| ▸ | MMP2 | P08253 | 7/20 | 0.55 |
| ▸ | AGTR2 | P50052 | 4/20 | 0.46 |
| ▸ | ANPEP | P15144 | 4/20 | 0.46 |
| ▸ | CTSL | P07711 | 1/20 | 0.41 |
| ▸ | CTSB | P07858 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Danegaptide SCHEMBL4040777 | 1.00 | MMP2 (0.55) | MMP2AGTR2ANPEPACECTSL | |
| Danegaptide SCHEMBL4040780 | 1.00 | MMP2 (0.55) | MMP2AGTR2ANPEPACECTSL | |
| Danegaptide SCHEMBL3103299 | 1.00 | MMP2 (0.55) | MMP2AGTR2ANPEPACECTSL | |
| Danegaptide SCHEMBL3109806 | 0.99 | MMP2 (0.54) | MMP2AGTR2ANPEPACECTSL | |
| Danegaptide SCHEMBL4037108 | 0.99 | MMP2 (0.54) | MMP2AGTR2ANPEPACECTSL | |
| Danegaptide SCHEMBL4037111 | 0.99 | MMP2 (0.54) | MMP2AGTR2ANPEPACECTSL | |
| Danegaptide SCHEMBL2399760 | 0.99 | MMP2 (0.56) | MMP2AGTR2ANPEPACECTSL | |
| Danegaptide SCHEMBL20547963 | 0.99 | MMP2 (0.56) | MMP2AGTR2ANPEPACECTSL | |
| Danegaptide SCHEMBL2399763 | 0.99 | MMP2 (0.56) | MMP2AGTR2ANPEPACECTSL | |
| Danegaptide SCHEMBL29094836 | 0.99 | MMP2 (0.56) | MMP2AGTR2ANPEPACECTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9469609-B2 | Synthesis of pyrrolidine compounds | ZEALAND PHARMA A/S (DK) | 2016-10-18 | — | — | US | claimed |
| US-20150322007-A1 | SYNTHESIS OF PYRROLIDINE COMPOUNDS | ZEALAND PHARMA A/S (DK) | 2015-11-12 | — | — | US | claimed |
| US-20130053344-A1 | SYNTHESIS OF PYRROLIDINE COMPOUNDS | ZEALAND PHARMA A/S (DK) | 2013-02-28 | — | — | US | claimed |
| US-20100249207-A1 | SYNTHESIS OF PYRROLIDINE COMPOUNDS | WYETH LLC (US) | 2010-09-30 | — | — | US | claimed |
| US-20080188545-A1 | (2S,4R)-1-(2-aminoacetyl)-4-benzamidopyrrolidine-2-carboxylic acid hydrochloride monohydrate; cardiovascular disease; osteoporosis; inflammation of airway epithelium; disorders of alveolar tissue; bladder incontinence; impaired hearing; endothelial lesions | ZEALAND PHARMA A/S (DK) | 2008-08-07 | — | — | US | claimed |
| EP-4739309-A1 | DANEGAPTIDE FOR USE IN TREATING SYNUCLEINOPATHIES | Cambridge Enterprise Limited (GB) | 2026-05-13 | — | — | EP | disclosed |
| EP-4452260-B1 | GAP JUNCTION MODULATORS AND THEIR USE FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION | BREYE THERAPEUTICS APS (DK) | 2026-01-28 | — | — | EP | disclosed |
| EP-3782649-B1 | BIODEGRADABLE POLYETHYLENE GLYCOL BASED WATER-INSOLUBLE HYDROGELS | ASCENDIS PHARMA AS (DK) | 2025-05-14 | — | — | EP | disclosed |
| US-20250049758-A1 | Danegaptide Formulation for Application in the Eye | BREYE THERAPEUTICS APS (DK) | 2025-02-13 | — | — | US | disclosed |
| US-20250018002-A1 | Gap Junction Modulators and Their Use for the Treatment of Age-Related Macular Degeneration | BREYE THERAPEUTICS APS (DK) | 2025-01-16 | — | — | US | disclosed |
| WO-2025008625-A1 | DANEGAPTIDE FOR USE IN TREATING SYNUCLEINOPATHIES | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2025-01-09 | — | — | WO | disclosed |
| EP-4452260-A1 | GAP JUNCTION MODULATORS AND THEIR USE FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION | Breye Therapeutics ApS (DK) | 2024-10-30 | — | — | EP | disclosed |
| US-8026272-B2 | Modified lysine-mimetic compounds | ZEALAND PHARMA A/S (DK) | 2011-09-27 | — | — | US | disclosed |
| US-20100249207-A1 | SYNTHESIS OF PYRROLIDINE COMPOUNDS | WYETH LLC (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100249207-A1 | SYNTHESIS OF PYRROLIDINE COMPOUNDS | WYETH LLC (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100249206-A1 | MODIFIED LYSINE-MIMETIC COMPOUNDS | Zealand Pharma A/S and Wyeth | 2010-09-30 | — | — | US | disclosed |
| US-7622496-B2 | antiarrhythmia agents; 1-(2-Amino-acetyl)-4-(benzoylamino)-pyrrolidine-2-carboxylic acid; desirable bioavailability properties | ZEALAND PHARMA A/S (DK) | 2009-11-24 | — | — | US | disclosed |
| US-20080188545-A1 | (2S,4R)-1-(2-aminoacetyl)-4-benzamidopyrrolidine-2-carboxylic acid hydrochloride monohydrate; cardiovascular disease; osteoporosis; inflammation of airway epithelium; disorders of alveolar tissue; bladder incontinence; impaired hearing; endothelial lesions | ZEALAND PHARMA A/S (DK) | 2008-08-07 | — | — | US | disclosed |
| US-20080188545-A1 | (2S,4R)-1-(2-aminoacetyl)-4-benzamidopyrrolidine-2-carboxylic acid hydrochloride monohydrate; cardiovascular disease; osteoporosis; inflammation of airway epithelium; disorders of alveolar tissue; bladder incontinence; impaired hearing; endothelial lesions | ZEALAND PHARMA A/S (DK) | 2008-08-07 | — | — | US | disclosed |
| US-20070149460-A1 | Modified lysine-mimetic compounds | ZEALAND PHARMA A/S (DK) | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130053344-A1 | SYNTHESIS OF PYRROLIDINE COMPOUNDS | CPS1, DHPS, DDC | ACE 1181/4885MMP2 3894/4885AGTR2 1599/4885 |
| US-20150322007-A1 | SYNTHESIS OF PYRROLIDINE COMPOUNDS | CPS1, DHPS, DDC | ACE 1181/4885MMP2 3894/4885AGTR2 1599/4885 |
| US-20080188545-A1 | (2S,4R)-1-(2-aminoacetyl)-4-benzamidopyrrolidine-2-carboxylic acid hydrochloride monohydrate; cardiovascular disease; osteoporosis; inflammation of airway epithelium; disorders of alveolar tissue; bladder incontinence; impaired hearing; endothelial lesions | GLS, COL2A1, MYOC | ACE 411/4885MMP2 970/4885AGTR2 61/4885 |
| US-20250018002-A1 | Gap Junction Modulators and Their Use for the Treatment of Age-Related Macular Degeneration | GJA1, GJB2, VEGFA | ACE 2233/4885MMP2 375/4885AGTR2 554/4885 |
| US-20100249206-A1 | MODIFIED LYSINE-MIMETIC COMPOUNDS | MYLK2, KCNN2, KCNN1 | ACE 863/4885MMP2 1902/4885AGTR2 715/4885 |
| US-20100249207-A1 | SYNTHESIS OF PYRROLIDINE COMPOUNDS | CPS1, DHPS, DDC | ACE 1181/4885MMP2 3894/4885AGTR2 1599/4885 |
| US-20070149460-A1 | Modified lysine-mimetic compounds | MYLK2, KCNN2, KCNN1 | ACE 863/4885MMP2 1902/4885AGTR2 715/4885 |
| US-20250049758-A1 | Danegaptide Formulation for Application in the Eye | VIP, HM13, PDE6C | ACE 543/4885MMP2 692/4885AGTR2 2045/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.